In April 2020, SG received accelerated approval for patients with metastatic TNBC who have received at least two prior therapies for metastatic disease (ASCENT trial).82 Subsequently, in February 2023 the FDA approved SG for patients with unresectable locally advanced or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/in situ hybridization negative [ISH-]) breast cancer who have received endocrine-based therapy and at least two prior systemic therapies in the metastatic setting based on the TROPiCS-02 trial.83,84. This evidence concerns the gene ERBB2 and breast carcinoma.